Novartis and Qualcomm are to develop a 'smart' COPD inhaler to allow patients to digitally monitor their medication. The announcement follows similar plans by Novartis's rivals in the respiratory ...

Smart inhaler tech company Propeller Health is collaborating with Novartis to bring its add-on sensor to its dry powder Breezhaler inhalers. Propeller's simple clip on sensor attaches to most ...

Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...

The FDA approved Novartis' Fabhalta, making it the first and only treatment for adults with C3 glomerulopathy. Fabhalta showed sustained proteinuria reduction in Phase 3 trials, with effects seen ...

Additionally, these medications are being evaluated for ... in front of a laboratory sample of healthcare products. Novartis AG (NYSE:NVS) is a Swiss global healthcare company that develops ...